CURRENT
ISSUE
1578
August 12, 2019

Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive disorder and posttraumatic stress disorder are now considered separate entities in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); they can also be treated with CBT and many of the same drugs.1

PHARMACOTHERAPY

Many different classes of drugs are used for treatment of...  Continue reading

More from Issue 1578
Previous Issue: 1577      July 29, 2019
Coming Soon
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Insect Repellents
Qmiiz ODT - An Orally Disintegrating Meloxicam Tablet
Drugs for Atrial Fibrillation
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1578

The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients ≥6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning.1,2 It is being marketed specifically for patients who have disruptive ADHD symptoms in the ... Continue reading